Compass Therapeutics (CMPX) Interest & Investment Income (2019 - 2026)
Compass Therapeutics (CMPX) posted Interest & Investment Income of -$439000.0 for Q1 2026, down 7416.67% sequentially from $6000.0 in Q4 2025, and down 2095.0% YoY from $22005.0 in Q1 2025.
Powered by 
Analysis
Compass Therapeutics (CMPX) Interest & Investment Income (2019 - 2026) Analysis & Trends
Compass Therapeutics has reported Interest & Investment Income for 8 years, with the latest figure at -$439000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 2095.0% year-over-year to -$439000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$349000.0 (down 224.64% YoY) and the FY2025 annual result came in at $70000.0, down 59.54% from the prior year.
- Interest & Investment Income declined to -$439000.0 in Q1 2026 per CMPX's latest filing, from $6000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $3.0 million in Q4 2022 and troughed at -$512000.0 in Q2 2022.
- A 5-year average of $203437.5 and a median of $12000.0 in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2026: Interest & Investment Income surged 62200.0% in 2022, then plunged 2095.0% in 2026.
- Over 5 years, Interest & Investment Income stood at $3.0 million in 2022, then plunged by 84.44% to $467000.0 in 2023, then sank by 159.1% to -$276000.0 in 2024, then surged by 102.17% to $6000.0 in 2025, then tumbled by 7416.67% to -$439000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$439000.0, $6000.0, and $66000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Compass Therapeutics | 452.99 Mn | 452.99 Mn | - | -92,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -92,000.00 |
| Mar 31, 2026 | -439,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | -20,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -127,000.00 |
| Dec 31, 2023 | 467,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | -361,000.00 |
| Mar 31, 2023 | 156,000.00 |
| Dec 31, 2022 | 1.29 Mn |
| Sep 30, 2022 | 623,000.00 |
| Jun 30, 2022 | -512,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 15,000.00 |